BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 28671458)

  • 1. Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors.
    Ho SY; Alam J; Jeyaraj DA; Wang W; Lin GR; Ang SH; Tan ESW; Lee MA; Ke Z; Madan B; Virshup DM; Ding LJ; Manoharan V; Chew YS; Low CB; Pendharkar V; Sangthongpitag K; Hill J; Keller TH; Poulsen A
    J Med Chem; 2017 Aug; 60(15):6678-6692. PubMed ID: 28671458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration of the linkage elements of porcupine antagonists led to potent Wnt signaling pathway inhibitors.
    Dong Y; Li K; Xu Z; Ma H; Zheng J; Hu Z; He S; Wu Y; Sun Z; Luo L; Li J; Zhang H; Zhang X
    Bioorg Med Chem; 2015 Nov; 23(21):6855-68. PubMed ID: 26455655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacophore Model for Wnt/Porcupine Inhibitors and Its Use in Drug Design.
    Poulsen A; Ho SY; Wang W; Alam J; Jeyaraj DA; Ang SH; Tan ES; Lin GR; Cheong VW; Ke Z; Lee MA; Keller TH
    J Chem Inf Model; 2015 Jul; 55(7):1435-48. PubMed ID: 26024410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the 'reversed' amide scaffold.
    Xu Z; Xu X; O'Laoi R; Ma H; Zheng J; Chen S; Luo L; Hu Z; He S; Li J; Zhang H; Zhang X
    Bioorg Med Chem; 2016 Nov; 24(22):5861-5872. PubMed ID: 27692509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Porcupine inhibitors: Novel and emerging anti-cancer therapeutics targeting the Wnt signaling pathway.
    Shah K; Panchal S; Patel B
    Pharmacol Res; 2021 May; 167():105532. PubMed ID: 33677106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and evaluation of potent Wnt signaling inhibitors featuring a fused 3-ring system.
    Xu Z; Li J; Wu Y; Sun Z; Luo L; Hu Z; He S; Zheng J; Zhang H; Zhang X
    Eur J Med Chem; 2016 Jan; 108():154-165. PubMed ID: 26647303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.
    Ma H; Chen Q; Zhu F; Zheng J; Li J; Zhang H; Chen S; Xing H; Luo L; Zheng LT; He S; Zhang X
    Eur J Med Chem; 2018 Apr; 149():110-121. PubMed ID: 29499483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and Optimization of a Porcupine Inhibitor.
    Duraiswamy AJ; Lee MA; Madan B; Ang SH; Tan ES; Cheong WW; Ke Z; Pendharkar V; Ding LJ; Chew YS; Manoharan V; Sangthongpitag K; Alam J; Poulsen A; Ho SY; Virshup DM; Keller TH
    J Med Chem; 2015 Aug; 58(15):5889-99. PubMed ID: 26110200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of porcupine inhibitors to target Wnt-driven cancers.
    Ho SY; Keller TH
    Bioorg Med Chem Lett; 2015 Dec; 25(23):5472-6. PubMed ID: 26522946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.
    Liu J; Pan S; Hsieh MH; Ng N; Sun F; Wang T; Kasibhatla S; Schuller AG; Li AG; Cheng D; Li J; Tompkins C; Pferdekamper A; Steffy A; Cheng J; Kowal C; Phung V; Guo G; Wang Y; Graham MP; Flynn S; Brenner JC; Li C; Villarroel MC; Schultz PG; Wu X; McNamara P; Sellers WR; Petruzzelli L; Boral AL; Seidel HM; McLaughlin ME; Che J; Carey TE; Vanasse G; Harris JL
    Proc Natl Acad Sci U S A; 2013 Dec; 110(50):20224-9. PubMed ID: 24277854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Novel and Potent Stearoyl Coenzyme A Desaturase 1 (SCD1) Inhibitors as Anticancer Agents.
    Imamura K; Tomita N; Kawakita Y; Ito Y; Ono K; Nii N; Miyazaki T; Yonemori K; Tawada M; Sumi H; Satoh Y; Yamamoto Y; Miyahisa I; Sasaki M; Satomi Y; Hirayama M; Nishigaki R; Maezaki H
    Bioorg Med Chem; 2017 Jul; 25(14):3768-3779. PubMed ID: 28571972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
    Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y
    J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
    Wang H; Yu N; Chen D; Lee KC; Lye PL; Chang JW; Deng W; Ng MC; Lu T; Khoo ML; Poulsen A; Sangthongpitag K; Wu X; Hu C; Goh KC; Wang X; Fang L; Goh KL; Khng HH; Goh SK; Yeo P; Liu X; Bonday Z; Wood JM; Dymock BW; Kantharaj E; Sun ET
    J Med Chem; 2011 Jul; 54(13):4694-720. PubMed ID: 21634430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of the Porcupine Inhibitor WNT974 in Mice.
    Zhang LS; Lum L
    Methods Mol Biol; 2016; 1481():111-7. PubMed ID: 27590157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3.
    Atkinson JM; Rank KB; Zeng Y; Capen A; Yadav V; Manro JR; Engler TA; Chedid M
    PLoS One; 2015; 10(4):e0125028. PubMed ID: 25915038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds.
    Okaniwa M; Hirose M; Imada T; Ohashi T; Hayashi Y; Miyazaki T; Arita T; Yabuki M; Kakoi K; Kato J; Takagi T; Kawamoto T; Yao S; Sumita A; Tsutsumi S; Tottori T; Oki H; Sang BC; Yano J; Aertgeerts K; Yoshida S; Ishikawa T
    J Med Chem; 2012 Apr; 55(7):3452-78. PubMed ID: 22376051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NOTUM is a potential pharmacodynamic biomarker of Wnt pathway inhibition.
    Madan B; Ke Z; Lei ZD; Oliver FA; Oshima M; Lee MA; Rozen S; Virshup DM
    Oncotarget; 2016 Mar; 7(11):12386-92. PubMed ID: 26848981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade to pathological remodeling of infarcted heart tissue using a porcupine antagonist.
    Moon J; Zhou H; Zhang LS; Tan W; Liu Y; Zhang S; Morlock LK; Bao X; Palecek SP; Feng JQ; Williams NS; Amatruda JF; Olson EN; Bassel-Duby R; Lum L
    Proc Natl Acad Sci U S A; 2017 Feb; 114(7):1649-1654. PubMed ID: 28143939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of highly potent inhibitors for porcupine.
    Wang X; Moon J; Dodge ME; Pan X; Zhang L; Hanson JM; Tuladhar R; Ma Z; Shi H; Williams NS; Amatruda JF; Carroll TJ; Lum L; Chen C
    J Med Chem; 2013 Mar; 56(6):2700-4. PubMed ID: 23477365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a triazole class of highly potent Porcn inhibitors.
    You L; Zhang C; Yarravarapu N; Morlock L; Wang X; Zhang L; Williams NS; Lum L; Chen C
    Bioorg Med Chem Lett; 2016 Dec; 26(24):5891-5895. PubMed ID: 27876319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.